华熙生物科技股份有限公司股东减持股份计划公告

Core Viewpoint - The major shareholder, Guoshou Chengda, plans to reduce its stake in Huaxi Biological Technology Co., Ltd. by up to 9,633,564 shares, representing a maximum of 2.00% of the total share capital, through centralized bidding and block trading methods [3][11]. Shareholder Information - As of the announcement date, Guoshou Chengda directly holds 28,936,504 shares of Huaxi Biological, accounting for 6.01% of the total share capital [2][4]. Reduction Plan Details - The reduction plan allows for a maximum of 9,633,564 shares to be sold, with a maximum of 4,816,782 shares through centralized bidding and 4,816,782 shares through block trading, within a period from November 26, 2025, to February 23, 2026 [3][11]. - The reduction will be adjusted in case of any changes in share capital due to stock dividends, capital increases, or buybacks [3][11]. Commitment and Compliance - Guoshou Chengda has made commitments regarding the holding period and reduction intentions, stating that it will not transfer shares within 36 months from the listing date [6][7]. - The company will comply with relevant laws and regulations during the reduction process, including pre-disclosure of the reduction plan [9][10].